Pharma Pulse 1/24/25: The Ups and Downs of AI for Pharma Investors, Defining Diagnostic Criteria for Clinical Obesity & more

The Ups and Downs of AI for Pharma Investors

Ash Shehata from KPMG discusses how artificial technology has a lot to prove, although investors still see a lot of potential in it.

New Report Aims to Further Define Diagnostic Criteria for Clinical Obesity

The Commission aims to provide information for clinical decision making, therapeutic interventions, and public health strategies.

Purdue, Sackler Family Reach New $7.4 Billion Opioid Accord

Bankrupt Purdue Pharma LP and members of the billionaire Sackler family agreed to pay $7.4 billion to a group of US states and other parties to settle long-running litigation over OxyContin’s role in the deadly opioid epidemic.

AHF Wins $10+ Million Against Prime Therapeutics in PBM Price-Fixing Arbitration

In a ruling Friday, January 17, Arbitrator Stuart M. Widman found that Prime Therapeutics had violated federal (Sherman Act) and state (Minnesota) antitrust laws in its business dealings with AHF after Prime entered into and performed what was ruled to be a price-fixing collaboration with Express Scripts (ESI), a competing and even larger PBM.

Nicholas Saraceno on LinkedIn

Thanks for the chat, Amanda! Always great chatting with knowledgeable KOLs like yourself, and shoutout to Lisa for the introduction at Trade & Channel Strategies. Parts II and III of our conversation coming soon.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs